A Phase I, Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Oral Topotecan in Combination With Lapatinib in Subjects With Advanced Solid Tumors
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2015
At a glance
- Drugs Lapatinib (Primary) ; Topotecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 12 Mar 2010 Planned initiation date added to 1 Sep 2008 as reported by ClinicalTrials.gov.
- 12 Mar 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 15 Jan 2009 Planned initiation date changed from 1 Jun 2008 to 1 Sep 2008 as reported by ClinicalTrials.gov.